OBJECTIVES: Heart-lung transplantation has been established as an effective treatment for patients with advanced cardiopulmonary failure. Over the years, the number of operations performed has declined. In 2015, only 38 adult heart-lung transplants were reported worldwide. Since then, we have performed 16 operations in high-acuity patients with excellent postoperative outcomes. Herein, we review our single-centre experience with heart-lung transplantation over the past 10 years.
INTRODUCTION
Heart-lung transplantation (HLTx) has been well established as an effective and definitive treatment for patients with advanced cardiopulmonary failure since its first success at the Stanford University Hospital in 1982 [1] . Since then, approximately 4000 patients have undergone HLTx. Over the last few decades, the number of HLTx, which peaked in 1989, gradually declined and finally was at its lowest in 2015 with 38 patients in total reported as having undergone HLTx, according to the International Society for Heart & Lung Transplantation (ISHLT) database. Furthermore, in 2009-2016, 63% of heart-lung transplant centres reported an average of 1 procedure per year [2] . This is likely due to the lower threshold to opt for heart-only or double-lung transplants due to its availability.
At our institution, we were able to observe a similar trend during the past decade with a constant decline in the number of HLTx with a trough of 0 patients in 2015. However, since January 2016 to April 2018, we have performed 16 heart-lung transplants (Fig. 1) . This study presents an overview of the patient characteristics and outcomes of our institution's heart-lung transplantation over the past 10 years with analyses of the previous era compared with the most recent era.
METHODS

Data collection
We retrospectively reviewed our experience with heart-lung transplants over the past 10 years at the Stanford University Hospital between January 2008 and July 2018. During this period, 49 consecutive adult patients underwent HLTx. Baseline demographics included age, sex, body mass index (kg/m 2 ), blood type, primary diagnosis, history of diabetes, haemodialysis, preoperative mechanical circulatory support (MCS), a calculated lung allocation score (LAS) and total waitlist time. Intraoperative data examined included total allograft ischaemic time (min) and concomitant kidney transplantation (Table 1) . Postoperative outcomes collected were length of hospital stay (days), postoperative requirement of haemodialysis, MCS, 30-day mortality, 1-year mortality, overall mortality and rate of cerebrovascular accident (Table 2) .
Thoracic organ procurement and transplantation
Conventional procurement techniques were employed. Following systemic infusion of heparin, the aorta and pulmonary artery were cannulated. Prostaglandin solution was infused into the pulmonary artery to transiently reduce pulmonary vascular resistance. Following aortic cross-clamping, hypothermic antegrade cardioplegia with cold storage solution ('UW solution', University of Wisconsin, Madison, WI, USA) and Perfadex (XVIVO Perfusion, Goteborg, Sweden) were infused through the aorta and the pulmonary artery, respectively. The donor heart and lungs were then explanted en bloc and prepared for transport. After explantation of the recipient's thoracic organs, an opening was made on each side of the pericardium deep to the phrenic nerve, while ensuring that the phrenic nerve was minimally disturbed. The donor's lungs were then placed into the pleural cavities through these openings, followed by anastomoses of the main trunk of the trachea, the vena cavas and the ascending aorta.
Statistical analysis
Statistical analysis was performed using the SAS Software, version 9.4, by SAS Institute Inc. (Cary, NC, USA). Categorical variables are expressed as frequencies and percentages and compared using the Fisher's exact test. Continuous variables are expressed with mean ± standard deviation and median with first and third quartiles (Q 1 -Q 3 ) and compared using the Mann-Whitney U-test. The Kaplan-Meier curve was used to represent survival and compared using the log-rank test.
Immunosuppression
At Stanford, induction of interleukin-2 receptor antagonist was not routinely used until May 2017. However, all patients received maintenance immunosuppressive regimen consisting of a combination of tacrolimus, mycophenolate mofetil and prednisone. Target level of each medication was determined based on several variables including concurrent medications and comorbidities. 
RESULTS
Baseline characteristics
A total of 49 patients underwent en bloc HLTx at Stanford between January of 2008 and July 2018. Baseline data for all patients and between Era I and Era II are summarized in Table 1 .
Indications/diagnosis
Of 49 patients undergoing HLTx in this study, the most common primary diagnosis was idiopathic pulmonary hypertension (PH) (n = 17, 35% overall: n = 11, 37% in Era I and n = 6, 32% in Era II). Non-idiopathic PH accounted for 8% of the patients, with n = 4 (n = 2, 7% in Era I and n = 2, 11% in Era II). Six patients (12%) had cystic fibrosis (n = 3, 10% in Era I; n = 3, 16% in Era II).
A total of 10 patients had diabetes mellitus (20%), and there was no significant difference between the 2 eras (23% in Era I and 16% in Era II; P = 0.72). One patient (2.0%) was dependent on haemodialysis prior to HLTx. The mean creatinine was 0.98 ± 0.51 (median 0.9; Q 1 -Q 3 0.61-1.12). There was no statistically significant difference in preoperative serum creatinine between the 2 eras. The calculated LAS was 45.3 ± 19.9 and was significantly higher in the most recent era when compared to Era I (51.1 ± 19.8 in Era II and 41.6 ± 19.5 in Era I; P = 0.006). The median waitlist time was 105 days (Q 1 -Q 3 19-189), and there was no statistically significant difference between the 2 eras (median time 100.5 days, Q 1 -Q 3 19-256 in Era I and 105 days, Q 1 -Q 3 17-189 in Era II; P = 0.86). Five patients (10.2%) required extracorporeal membrane oxygenator (ECMO) leading up to the transplant (n = 1, 3% in Era I; n = 4, 21% in Era II; P = 0.067). Only 1 patient (2.0%) had a ventricular assist device at the time of the transplant.
Intraoperative variables
For the 49 patients, the median allograft ischaemic time was 3.60 h, Q 1 -Q 3 2.9-4.4 h. There was no significant difference in the total ischaemic times between the 2 eras (3.7 h, Q 1 -Q 3 2.4-4.6 in Era I and 3.5 h, Q 1 -Q 3 3.1-4.2 in Era II; P = 0.75). A total of 3 patients underwent a kidney transplant immediately following the HLTx (n = 1, 3% in Era I; n = 2, 11% in Era II; P = 0.55) ( Table 1) .
Clinical outcomes
The mean follow-up time was 3.2 ± 3.0 years (4.7 ± 3.03 years in Era I and 0.9 ± 0.7 years in Era II; P < 0.001) ( Table 2) . Postoperatively, 4 patients (8%) required intra-aortic balloon pump support. One patient (2.0%) required VA ECMO support. All 5 patients requiring MCS belonged to Era II. Haemodialysis was initiated on 10 patients (20%) (n = 9, 30% in Era I and n = 1, 5% in Era II; P = 0.066). 1 patient suffered a cerebrovascular accident (n = 1, 2.04% overall; 0% in Era I and 5.3% in Era II; P = 0.3878. The median length of hospital stay was overall 21.5 days with Q 1 -Q 3 of 12-47 (21 days, Q 1 -Q 3 11-55 in Era I and 22 days, Q 1 -Q 3 12-38 in Era II; P = 0.75). There were 2 deaths (4%) within 30 days of HLTx (n = 2, 7% in Era I and 0, 0% in Era II; P = 0.52). One-year mortality was 10% (n = 5), which all occurred in Era I. The 1-year mortality in Era II was 0%. This was, however, of no statistical significance (P = 0.14). As shown in Table 3 , the most common cause of death was chronic rejection (28.5%). The median survival time could not be calculated as survival probability remains higher than 50% (Fig. 2) .
DISCUSSION
The reported number of heart-lung transplants has been on the decline for the past few decades since the first HLTx in 1982.
Over the past 30 years, the lowest number of HLTxs was performed in 2015, with only 38 operations performed. However, HLTx remains an effective treatment for end-stage cardiopulmonary failure. At our institution, we were able to observe this decline in volume as well, with 0 HLTx performed in 2015.
However, since then, we have been experiencing a gradual rise at our centre. Since January 2016, we have performed 19 HLTx operations. Therefore, in this study, we sought not only to examine our institutional patient characteristics and outcomes but also to compare those parameters between the previous HLTx era ( [2008] [2009] [2010] [2011] [2012] [2013] [2014] [2015] and this current era (2016 to present). We performed a total of 49 heart-lung transplants between 2008 and 2018. There were 30 HLTxs between 2008 and 2015 and 19 HLTxs between 2016 and July 2018. Overall, our patients' baseline demographics were similar to the ISHLT 2017 Registry Report [2] . Most patients who underwent HLTx were younger than 50 years at the time of transplant. The most common primary diagnosis was idiopathic PH (35%). Overall PH-both idiopathic and non-idiopathic-was found to be 43% of the patients in our cohort. This is consistent with the trend reported in the 2017 Registry, where approximately 66% of patients in the past 20 years had PH as their primary indication or diagnosis for HLTx. Although there were no statistically significant differences between the diagnoses across the 2 eras, we noted that the acuity and severity of disease appeared to be higher in the most recent CVA: cerebrovascular accident; ECMO: extracorporeal membrane oxygenation; HLTX: heart-lung transplant; IABP: intra-aortic balloon pump. era. This was observed in the higher LAS in Era II (P = 0.006) and the higher number of preoperative MCS, chronic haemodialysis and number of concomitant kidney transplant operations in Era II, although we were not able to demonstrate statistical significance. Our total allograft ischaemic time of 3.60 h (Q 1 -Q 3 2.9-4.4) also appeared to be similar across the eras (P = 0.75) and comparable to the 2017 Registry's report of a median time of 3-4 h. Our overall median waitlist time was 105 days (Q 1 -Q 3 19-189) and did not exhibit a statistically significant difference across the eras.
At the time of follow-up (mean 3.2 years), there appeared to be no significant difference between patients' length of hospitalization, risk of postoperative haemodialysis, CVA, 30-day mortality or 1-year mortality. A total of 5 patients required MCS posttransplant (n = 4, 21% required intra-aortic balloon pump and n = 1, 5% required venoarterial ECMO). All 5 patients were in Era II, although this was not statistically significant.
Although the annual number of heart-lung transplants has been on the decline, at Stanford, we have been able to increase our volume of HLTxs over the past 2 years. Moreover, although there is a trend of higher acuity in patients in the present era (higher LAS, rate of preoperative haemodialysis and rate of MCS), we continue to have excellent outcomes with 100% 30-day survival and 1-year survival (the national survival rate in the USA in 2016 was 82.1%). This is a profound outcome considering that according to the United Network of Organ Sharing (UNOS) database, HLTx patients requiring ECMO had higher risk of mortality compared to those without ECMO [3] . Furthermore, in a study by Idrees et al. [4] HLTx was performed in 34 patients (1992-2014), of whom 7 required pre-or post-transplant ECMO, and 57% of these patients died.
One may argue that our results showed only short-term outcomes. However, historically, the conditional median survival of patients who underwent HTLx, defined as median survival in patients surviving to 1 year, is 10.3 years [2] . Therefore, following the survival trends after 1 year, we can expect even better longterm outcomes and median survival in our patients. This is likely due to improved surgical techniques, organ preservation solutions, advances in immunosuppression regimen, and the trend towards embracing preoperative and postoperative use of temporary MCS. Moreover, we have also adopted an interdisciplinary approach for postoperative patient care between the surgical team, critical care team, pulmonologists, pharmacists and designated 'transplant' ancillary staff (e.g. case managers, social workers and nutritionists).
These results suggest that in a high-volume heart-lung transplant programme, excellent postoperative outcomes can be achieved even in patients with progressive cardiopulmonary decline and that, to this day, HTLx remains a viable treatment option for patients with advanced cardiopulmonary disease.
